Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

"Amazon's Choice" Designation for Medical Grade Face Masks

Micron Technologies has been operating at the Company's facility in Delta, British Columbia since August 2020 where it manufactures three-ply medical grade face masks. In early April 2021 , Micron Technologies' three-ply medical grade face masks achieved the "Amazon's Choice" designation from Amazon. The "Amazon's Choice" designation is achieved by having a high star rating, competitive price, low return rate, consistent inventory, and high sales. Micron Technologies anticipates a sales boost following achieving the "Amazon's Choice" designation.

In addition to Amazon, Micron Technologies' products are available online at Walmart and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com .

Micron Technologies Accepting Bitcoin

Micron Technologies has entered the cryptocurrency space by now accepting Bitcoin as a form of payment for its products. The option to pay with Bitcoin is available to both retail and wholesale customers. Customers who wish to pay with Bitcoin can do so on Micron Technologies' website where the payment will be completed via BitPay, a Bitcoin service provider.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology.

The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2021/27/c4406.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less
Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares.

All matters put forward to shareholders for consideration and approval, as set out in the Company's Management Information Circular dated 22nd of February, 2024, were approved by the requisite majority of votes cast at the Meeting. These were:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×